On November 30, 2021, the U.S. Food and Drug Administration (FDA) approved daratumumab and hyaluronidase-fihj in combination with carfilzomib and dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma (MM) who have received one to three prior lines of therapy.
Read the FDA announcement.
Read Janssen, Inc.'s announcement.
Posted 12/2/2021
Understanding both the benefits to be had from offering BsAb therapy to its community and the scope of this undertaking, Vanderbilt-Ingram Cancer Center took a novel approach with its APP-led BsAb step-up dosing clinic, which won the program a 2026 ACCC Innovator Award.
